About ExeVir Bio
ExeVir Bio is a company based in Ghent (Belgium) founded in 2020. ExeVir Bio has raised $49.64 million across 4 funding rounds from investors including European Investment Bank, VIB and European Union. The company has 11 employees as of December 31, 2022. ExeVir Bio offers products and services including VHH Antibody Platform and Antibody Therapies. ExeVir Bio operates in a competitive market with competitors including Pardes Biosciences, Vaxxinity, NRx, Inimmune and IMUNON, among others.
- Headquarter Ghent, Belgium
- Employees 11 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exevir Bio
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.64 M (USD)
in 4 rounds
-
Latest Funding Round
$26.61 M (USD), Debt – Venture
Jan 09, 2023
-
Investors
European Investment Bank
& 10 more
-
Employee Count
11
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ExeVir Bio
ExeVir Bio offers a comprehensive portfolio of products and services, including VHH Antibody Platform and Antibody Therapies.
Platform for creating multi-specific antibodies against infectious diseases
Therapies to prevent and treat diseases like COVID-19 and dengue
People of ExeVir Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ExeVir Bio
ExeVir Bio has successfully raised a total of $49.64M across 4 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $26.61 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ExeVir Bio
ExeVir Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, VIB and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Fund+ is focused on investing in life sciences companies.
|
Locked | Locked | Locked | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Locked | Locked | Locked |
Investor details for ExeVir Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ExeVir Bio
Investment portfolio details for ExeVir Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ExeVir Bio
Detailed financials for ExeVir Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exevir Bio Comparisons
Peer comparison for ExeVir Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ExeVir Bio
ExeVir Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pardes Biosciences, Vaxxinity, NRx, Inimmune and IMUNON, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| Locked | Locked | Locked |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for COVID-19 and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed using DNA-based platforms.
|
Detailed competitors of ExeVir Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exevir Bio
Complete news archive for ExeVir Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ExeVir Bio
ExeVir Bio was founded in 2020.
ExeVir Bio is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Torsten Mummenbrauer is the current CEO of ExeVir Bio.
ExeVir Bio is a funded company, having raised a total of $49.64M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at ExeVir Bio is 11.
ExeVir Bio was founded in 2020 in Ghent, Belgium, within the biotechnology sector. Single-domain antibody fragments, known as VHH, derived from camelids are developed for monitoring and addressing viral infections. The lead product, VHH72-FC, targets conserved spike regions of SARS-CoV-2 to inhibit viral entry into cells, halt replication, and aid immune responses by lowering viral loads and reducing inflammation in affected areas.
ExeVir Bio's top competitors include NRx, Cell BioEngines and Pardes Biosciences.
ExeVir Bio offers VHH Antibody Platform and Antibody Therapies.
ExeVir Bio has 11 investors. Key investors include European Investment Bank, VIB, European Union, Fund+, and UCB Ventures.